THC Farmaceuticals, Inc. (CBDG)
OTCMKTS
· Delayed Price · Currency is USD
0.0130
0.00 (0.00%)
May 9, 2025, 4:00 PM EDT
THC Farmaceuticals Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | 2009 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '15 Jun 30, 2015 | Sep '14 Sep 30, 2014 | Sep '13 Sep 30, 2013 | Sep '12 Sep 30, 2012 | Sep '11 Sep 30, 2011 | Sep '10 Sep 30, 2010 | 2009 |
| Revenue | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.04 | Upgrade
|
| Revenue Growth (YoY) | -1.50% | -12.04% | -29.23% | -10.48% | -10.55% | -4.80% | Upgrade
|
| Cost of Revenue | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | Upgrade
|
| Gross Profit | 0 | 0.01 | 0 | 0.01 | 0.02 | 0.03 | Upgrade
|
| Selling, General & Admin | 0.07 | 0.03 | 0.02 | 0.04 | 0.04 | 0.02 | Upgrade
|
| Operating Expenses | 0.07 | 0.03 | 0.02 | 0.04 | 0.05 | 0.03 | Upgrade
|
| Operating Income | -0.07 | -0.02 | -0.02 | -0.02 | -0.02 | 0 | Upgrade
|
| Interest Expense | -0 | -0.01 | -0 | -0 | -0 | -0 | Upgrade
|
| EBT Excluding Unusual Items | -0.07 | -0.03 | -0.02 | -0.03 | -0.03 | -0 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0 | - | -0 | Upgrade
|
| Asset Writedown | - | - | - | -0.01 | - | -0.01 | Upgrade
|
| Pretax Income | -0.07 | -0.03 | -0.02 | -0.04 | -0.03 | -0.01 | Upgrade
|
| Net Income | -0.07 | -0.03 | -0.02 | -0.04 | -0.03 | -0.01 | Upgrade
|
| Net Income to Common | -0.07 | -0.03 | -0.02 | -0.04 | -0.03 | -0.01 | Upgrade
|
| Shares Outstanding (Basic) | 13 | 9 | 9 | 9 | 9 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 13 | 9 | 9 | 9 | 9 | 5 | Upgrade
|
| Shares Change (YoY) | 50.42% | - | - | - | 69.35% | 2.08% | Upgrade
|
| EPS (Basic) | -0.01 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | Upgrade
|
| Free Cash Flow | -1.51 | -0.02 | -0.02 | -0.02 | 0.02 | 0 | Upgrade
|
| Free Cash Flow Per Share | -0.11 | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 | Upgrade
|
| Gross Margin | 23.86% | 35.38% | 22.37% | 45.06% | 64.32% | 68.58% | Upgrade
|
| Operating Margin | -378.15% | -126.18% | -90.50% | -76.96% | -69.52% | 1.56% | Upgrade
|
| Profit Margin | -391.34% | -161.27% | -110.15% | -129.80% | -83.02% | -28.18% | Upgrade
|
| Free Cash Flow Margin | -8146.50% | -99.31% | -88.78% | -72.69% | 60.22% | 7.99% | Upgrade
|
| EBITDA | -0.07 | -0.02 | -0.02 | -0.02 | -0.02 | 0 | Upgrade
|
| EBITDA Margin | - | -123.03% | -85.66% | -72.30% | -50.60% | 6.57% | Upgrade
|
| D&A For EBITDA | 0 | 0 | 0 | 0 | 0.01 | 0 | Upgrade
|
| EBIT | -0.07 | -0.02 | -0.02 | -0.02 | -0.02 | 0 | Upgrade
|
| EBIT Margin | - | -126.18% | -90.50% | -76.96% | -69.52% | 1.56% | Upgrade
|
| Revenue as Reported | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.04 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.